Source link : https://www.newshealth.biz/health-news/osimertinib-yields-phenomenal-gains-in-pfs-for-stage-iii-egfr-mutant-nsclc/
In this exclusive MedPage Today video, Roy Herbst, MD, PhD, of Yale Cancer Center in New Haven, Connecticut, discusses exciting new data surrounding osimertinib (Tagrisso) in patients with EGFR-mutated non-small cell lung cancer (NSCLC) from both the LAURA and ADAURA trials, including improvements in progression-free survival (PFS) in stage III patients and the potential of […]
Author : News Health
Publish date : 2024-06-21 12:33:17
Copyright for syndicated content belongs to the linked Source.
Categories